Introduction {#sec1}
============

Transcatheter aortic valve implantation (TAVI) has become an alternative to surgical aortic valve replacement (SAVR) in intermediate and high-risk as well as inoperable patients with severe, symptomatic aortic stenosis. Patient-prosthesis mismatch (PPM) is a phenomenon in which the effective orifice area (EOA) of the otherwise functional valve is too small in relation to the patient. Incongruence is considered moderate in cases with aortic valve area indexed (AVAi) to body surface area less than 0.85 cm^2^/m^2^ and severe when below 0.65 cm^2^/m^2^ \[[@cit0001]\]. Patient-prosthesis mismatch in patients treated with SAVR has been shown to negatively impact functional class improvement and exercise tolerability and increase the adverse event rate as well as late mortality \[[@cit0002], [@cit0003]\].

The impact on survival and functional recovery of the same phenomenon in patients undergoing TAVI is not equally apparent.

Aim {#sec2}
===

We sought to further evaluate the predictors, the incidence and the importance for prognosis of PPM.

Material and methods {#sec3}
====================

Study design and population {#sec3.1}
---------------------------

Two hundred and thirty-eight consecutive inoperable or high-risk patients with severe symptomatic aortic stenosis (aortic valve area (AVA) \< 1.0 cm^2^ or indexed valve area less than 0.6 cm^2^/m^2^ or mean gradient \> 40 mm Hg or maximum jet velocity \> 4.0 m/s or velocity ratio \< 0.25) who after the heart team's decision underwent TAVI in a university heart center between March 2010 and March 2016 were screened. Both balloon- and self-expanding aortic valve prostheses of the first and second generation were used and all standard delivery routes were applied, with predominant use of transfemoral access. It was an all-comers study, and the only exclusion criterion was lack of a complete post-procedural echocardiographic study. Informed consent was obtained from all participating patients, and the local ethics committee granted permission for the study.

Definitions, echocardiographic data {#sec3.2}
-----------------------------------

Transthoracic echocardiography was performed at baseline and before discharge using the Philips Epiq 7C with x5-1 probe. Complete echocardiographic studies were performed in a standard fashion and analyzed by a single experienced echocardiographer. The left ventricular (LV) ejection fraction was calculated using the Simpson method. Low-gradient aortic stenosis was defined by a mean transaortic gradient of \< 40 mm Hg and an LV ejection fraction of \< 35% \[[@cit0004]\]. Before the procedure, AVA was estimated using the continuity equation approach (AVA = LV outflow tract (LVOT) area × velocity time integral~LVOT~/velocity time integral~valve~). After implantation, LVOT area was measured directly underneath the prosthesis, assuming a circular geometry. In order to correctly assess EOA, the pulse wave Doppler sample was located in the LVOT, adjacent to the in-flow segment of the prosthesis but not inside it, avoiding the region of subvalvular acceleration as previously described \[[@cit0005], [@cit0006]\]. The indexed EOA was calculated by dividing the EOA by the patient's body surface area (BSA).

The PPM was defined as follows: no PPM if the indexed EOA was \> 0.85 cm^2^/m^2^, moderate PPM if between 0.65 and 0.85 cm^2^/m^2^, and severe PPM when \< 0.65 cm^2^/m^2^.

Follow-up and endpoints {#sec3.3}
-----------------------

Only patients discharged alive were included in the analysis. Clinical follow-up was performed either during a follow-up hospitalization or ambulatory visit 1, 6 and 12 months after the index hospitalization. Civil registries were additionally reviewed in order to assess patients' vital status.

The primary endpoint was all-cause mortality after discharge and up to 1 year follow-up, and the secondary endpoint was clinical efficacy after 30 days -- a composite of all-cause mortality, all stroke, hospitalization for valve-related symptoms or worsening congestive heart failure, NYHA class III or IV or valve-related dysfunction (mean aortic valve gradient ≥ 20 mm Hg or moderate or severe prosthetic aortic valve regurgitation) as proposed by Valve Academic Research Consortium-2 (VARC-2) \[[@cit0007]\]. Patient-prosthesis mismatch -- part of the original endpoint -- was removed from the composite.

Statistical analysis {#sec3.4}
--------------------

Continuous variables, expressed as means ± SD, were compared between the PPM and no PPM groups as well as between patients with and without an endpoint using Student's *t*-test or the Mann-Whitney *U*-test depending on the distribution pattern. The Shapiro-Wilk test was used to confirm or reject normal distribution of each continuous variable. Categorical variables, expressed as counts and percentages, were compared using the χ^2^ test or Fisher's exact test, as appropriate.

A univariate backwards likelihood ratio logistic regression model was used to identify predictors of the primary endpoint and its components.

Variables from the univariate analysis and baseline variables that were different between patients with and without PPM (with a *p*-value ≤ 0.10) were included in the multivariate analysis. Results are presented as the odds ratio (OR) with 95% confidence interval.

All probability values reported are 2-sided and a value \< 0.05 was considered to be significant. All data were processed using SPSS software, version 22 (IBM SPSS Statistics, New York, US).

Results {#sec4}
=======

Population characteristics {#sec4.1}
--------------------------

Of the 238 consecutive patients screened, complete post-procedural echocardiograms were either not available to the researchers or of suboptimal quality in 14 patients. Eighteen (7.6%) patients were excluded due to peri-procedural or in-hospital non-valve-related death. Five patients in whom valve-in-valve TAVI for failed surgical prostheses was performed were also excluded. The overall study population consisted of 201 patients. The mean age was 79.6 years, there were 105 (52%) females, over 75% of patients had hypertension, 40% had diabetes and almost half (47.3%) were in New York Heart Association (NYHA) class III or IV. Detailed baseline characteristics of the study population are shown in [Table I](#t0001){ref-type="table"}.

###### 

Baseline, procedural and postprocedural characteristics of the entire cohort and within the PPM and no PPM groups

  -----------------------------------------------------------------------------------------------------------
  Parameter                              Total\        Any PPM\             No PPM\               *P*-value
                                         *N* = 201     (*n* = 48) (23.9%)   (*n* = 153) (76.1%)   
  -------------------------------------- ------------- -------------------- --------------------- -----------
  Baseline:                                                                                       

   Age \[years\]                         79.63 ±7.4    79.25 ±7.6           79.75 ±7.4            0.95

   Female sex, *n* (%)                   105 (52.2)    27 (56.3)            78 (51)               0.52

   Body surface area \[m^2^\]            1.81 ±0.18    1.88 ±0.2            1.79 ±0.2             0.01

   NYHA III/IV, *n* (%)                  95 (47.3)     23 (47.9)            72 (47.1)             0.92

   Hypertension, *n* (%)                 151 (75.5)    34 (72.3)            117 (76.5)            0.57

   Diabetes, *n* (%)                     78 (39)       18 (38.3)            60 (39.2)             0.91

   COPD, *n* (%)                         37 (18.4)     11 (22.9)            26 (17)               0.36

   Atrial fibrillation, *n* (%)          70 (35)       18 (38.3)            52 (34)               0.59

   History of MI, *n* (%)                46 (22.9)     8 (16.7)             38 (24.8)             0.24

   History of stroke, *n* (%)            43 (21.4)     11 (22.9)            32 (20.9)             0.77

   GFR \< 30 ml/min/1.73 m^2^, *n* (%)   21 (10.4)     3 (6.3)              18 (11.8)             0.28

   Ejection fraction (%)                 51.1 ±13.9    50.93 ±11.6          51.14 ±14.5           0.52

   Bicuspid aortic valve, *n* (%)        16 (8)        5 (10.4)             11 (7.2)              0.54

   AVA \[cm^2^\]                         0.76 ±0.4     0.72 ±0.2            0.77 ±0.5             0.95

   AVAi \[cm^2^/m^2^\]                   0.42 ±0.2     0.38 ±0.9            0.43 ±0.2             0.5

   PGmax \[mm Hg\]                       78.71 ±29.1   82.31 ±33.9          77.61 ±27.4           0.73

   PGmean \[mm Hg\]                      47.19 ±18.1   48.36 ±19.7          46.83 ±17.6           0.9

  Procedural, *n* (%):                                                                            

   Transfemoral access                   159 (79.1)    34 (70.8)            125 (81.7)            0.11

   Predilatation                         141 (70.5)    37 (77.1)            104 (68.4)            0.28

   Self-expanding valve                  137 (68.2)    32 (66.7)            105 (68.6)            0.8

   Valve size ≤ 26 mm                    80 (39.8)     21 (43.8)            59 (38.6)             0.52

   Postdilatation                        42 (21)       6 (12.5)             36 (23.7)             0.1

  Postprocedural:                                                                                 

   Ejection fraction (%)                 54.78 ±12.2   57.72 ±8.9           53.9 ±12.9            0.19

   EOA \[cm^2^\]                         1.7 ±0.2      1.44 ±0.2            1.78 ±0.2             \< 0.001

   EOAi \[cm^2^/m^2^\]                   0.94 ±0.1     0.77 ±0.1            1 ±0.1                \< 0.001

   PGmax \[mm Hg\]                       19.7 ±12.9    24.69 ±13.4          18.16 ±12.3           \< 0.001

   PGmean \[mm Hg\]                      10.44 ±5.7    14.35 ±8             9.19 ±4               \< 0.001
  -----------------------------------------------------------------------------------------------------------

AVA -- aortic valve area, AVAi -- indexed aortic valve area, COPD -- chronic obstructive pulmonary disease, EOA -- effective orifice area, EOAi -- indexed effective orifice area, GFR -- glomerular filtration rate, NYHA -- New York Heart Association, PG -- pressure gradient.

Patient-prosthesis mismatch incidence and predictors {#sec4.2}
----------------------------------------------------

Any PPM was present in 48 (23.9%) subjects, 7 of whom had severe PPM (3.5% of the group, 14.5% of the PPM cohort). Patients with any PPM had higher body surface area (BSA) and trended towards lower frequency of bioprosthesis post-dilation ([Table I](#t0001){ref-type="table"}). In multivariate regression, BSA was found to be a highly independent predictor of PPM (OR = 16.9, *p* \< 0.001) whereas postdilation tended to have a protective effect against PPM after TAVI (OR = 0.46, *p* = 0.09) ([Table II](#t0002){ref-type="table"}).

###### 

Predictors of any PPM occurrence

  Parameter                                  Odds ratio (OR)   95% CI         *P*-value
  ------------------------------------------ ----------------- -------------- -----------
  Female sex                                 1.24              0.64--2.37     0.52
  Body surface area \[m^2^\]                 16.86             2.48--114.77   0.004
  Age \[years\]                              0.99              0.95--1.04     0.69
  Diabetes                                   0.96              0.49--1.88     0.91
  Hypertension                               0.81              0.38--1.69     0.57
  Chronic obstructive pulmonary disease      1.45              0.66--3.21     0.36
  Atrial fibrillation                        1.21              0.61--2.37     0.59
  Prior myocardial infarction                0.61              0.26--1.41     0.24
  Prior stroke                               1.12              0.52--2.45     0.77
  Ejection fraction (%)                      0.99              0.93--1.03     0.94
  Aortic valve area \[cm^2^\]                0.61              0.17--2.17     0.45
  Indexed aortic valve area \[cm^2^/m^2^\]   0.19              0.01--3.36     0.26
  Pressure gradient mean \[mm Hg\]           1.01              0.99--1.02     0.63
  Pressure gradient max \[mm Hg\]            1.01              0.99--1.02     0.36
  Annulus size \[mm\]                        0.95              0.85--1.05     0.32
  Bicuspid aortic valve                      1.5               0.49--4.56     0.47
  Prosthesis size ≤ 26 mm                    1.24              0.64--2.39     0.52
  Prosthesis size ≤ 23 mm                    1.21              0.37--3.97     0.75
  Self-expanding prosthesis                  0.91              0.46--1.82     0.8
  Predilatation                              1.55              0.73--3.3      0.25
  Postdilatation                             0.46              0.18--1.17     0.09

Endpoints {#sec4.3}
---------

At 1 year 27 patients had died (13.4%). Overall 95 (47.3%) patients met at least 1 element of the composite clinical efficacy endpoint in the 1-year follow-up. There were 8 (3.9%) strokes, 9 (4.4%) patients were in NYHA class III or higher, 20 (9.9%) had an unplanned hospitalization, 13 (6.5%) had a mean pressure gradient across the prosthesis higher than 20 mm Hg, 37 (18.4%) had moderate and 2 (0.9%) severe aortic regurgitation.

PPM and the primary endpoint {#sec4.4}
----------------------------

There was no difference in the rates of all-cause mortality in patients with severe (1/7, 14.3%), moderate (6/41, 14.6%) or no PPM (20/153, 13.1%; log-rank *p* = 0.98, [Figure 1](#f0001){ref-type="fig"}). Similarly, presence of PPM did not impact the occurrence of composite endpoint of clinical efficacy at 1 year ([Table III](#t0003){ref-type="table"}). When individual components were analyzed, both moderate and severe PPM significantly correlated with mean pressure gradient across the bioprosthesis greater than 20 mm Hg ([Table III](#t0003){ref-type="table"}). Finally, PPM also did not influence mortality at 1 year in patients without paravalvular regurgitation (OR = 1.17, 95% CI: 0.43--3.2, *p* = 0.76).

###### 

Impact of PPM on all-cause mortality, composite and individual endpoints of clinical efficacy

  Parameter                       Moderate PPM (*n* = 41) (20.4%)   Severe PPM (*n* = 7) (3.5%)                              
  ------------------------------- --------------------------------- ----------------------------- ------ ------ ------------ -------
  All-cause mortality             1.14                              0.43--3.05                    0.79   1.11   0.13--9.7    0.93
  Stroke                          1.26                              0.24--6.47                    0.79   --     --           --
  Unplanned hospitalization       1.07                              0.33--3.45                    0.91   3.97   0.7--22.4    0.12
  NYHA III/IV                     0.45                              0.06--3.73                    0.46   --     --           --
  PG mean \> 20 mm Hg             10.5                              1.96--56.2                    0.01   30.2   3.51--260    0.002
  AR moderate or severe           1.15                              0.5--2.67                     0.74   0.68   0.08--5.89   0.73
  Clinical efficacy (composite)   1.6                               0.8--3.2                      0.19   1.67   0.36--7.7    0.51

AR -- aortic regurgitation, NYHA -- New York Heart Association, PG -- pressure gradient, PPM -- patient-prosthesis mismatch.

![Kaplan-Meier mortality curves according to the presence of PPM and its severity. Log-rank *p* = 0.92 (severe PPM vs. no PPM) and log-rank *p* = 0.87 (moderate PPM vs. no PPM)](PWKI-13-31039-g001){#f0001}

Analysis of indexed EOA as a continuous variable also demonstrated no discriminatory power in terms of predicting all-cause mortality (area under the curve (AUC) 0.53, 95% CI: 0.42--0.65, *p* = 0.58) or the composite endpoint of clinical efficacy (AUC = 0.52, 95% CI: 0.44--0.6, *p* = 0.65) ([Figures 2](#f0002){ref-type="fig"} and [3](#f0003){ref-type="fig"}). However, there was a clear discriminatory ability of EOAi in terms of predicting mean pressure gradient \> 20 mm Hg after TAVI (AUC = 0.79, 95% CI: 0.62--0.96, *p* = 0.003) ([Figure 4](#f0004){ref-type="fig"}).

![Receiver-operating characteristics curve for indexed EOA and all-cause mortality at 1 year after TAVI](PWKI-13-31039-g002){#f0002}

![Receiver-operating characteristics curve for indexed EOA and composite clinical efficacy endpoint at 1 year after TAVI](PWKI-13-31039-g003){#f0003}

![Receiver-operating characteristics curve for indexed EOA and transvalvular pressure gradient \> 20 mm Hg after prosthesis implantation](PWKI-13-31039-g004){#f0004}

Discussion {#sec5}
==========

Prevalence and predictors of PPM {#sec5.1}
--------------------------------

In our study, any PPM was found in less than a quarter of patients but severe PPM was diagnosed only in 3.5% of patients. Those numbers are well within the range of currently available reports for moderate PPM \[[@cit0008], [@cit0009]\], and on the lower side of the range for severe PPM \[[@cit0006], [@cit0008], [@cit0010]--[@cit0015]\]. These data may reassure that in TAVI with the predominant use of self-expanding prostheses and transfemoral access in most cases and anatomies a large enough EOAi can be achieved to avoid severe PPM. In the present work, we have not compared the frequency of PPM after TAVI and SAVR. However, a number of publications \[[@cit0012], [@cit0016], [@cit0017]\] have reported that it is significantly less frequent after percutaneous treatment, with a recent meta-analysis showing that TAVI provides a 77% risk reduction of any mismatch as compared to SAVR \[[@cit0018]\].

In the analyzed population, the only predictor of PPM occurrence was BSA, a finding that is consistent with the available reports \[[@cit0009], [@cit0019]--[@cit0023]\]. A potential protective effect of bioprosthesis post-dilation on mismatch occurrence requires a larger sample size for confirmation. In this context, potentially adverse effects of post-dilation such as new bundle branch or atrioventricular block and stroke should be considered. We also cannot exclude that a similar percentage of PPM occurrence irrespective of the valve type used (self- vs. balloon-expanding) might also be potentially related to the limited sample size.

Impact of PPM on mid-term prognosis {#sec5.2}
-----------------------------------

In our study, there was no impact of either moderate or severe PPM on the occurrence of the clinical efficacy composite endpoint. Analysis of the endpoint components demonstrated a significant influence of mismatch on occurrence of high-pressure gradients (\> 20 mm Hg) across the aortic valve after TAVI, which is consistent with previous studies \[[@cit0009], [@cit0019]\]. Although a pressure difference is not part of the mismatch definition, its relation to a small effective orifice area is perfectly logical.

In regard to mortality, in the majority of available reports analyzing patients after TAVI no impact of PPM was found. In a recent meta-analysis \[[@cit0018]\], including 2654 patients, neither severe nor moderate mismatch influenced late mortality. Possible explanations of the lack of impact of PPM on survival in TAVI patients may include overestimation of mismatch in patients with a large BSA (e.g. obese subjects) along with the previously described "obesity paradox" \[[@cit0024]\] -- better long-term outcome of patients with an elevated body mass index. Secondly, a confounding effect of coexisting moderate or severe paravalvular regurgitation is suggested. In the PARTNER trial cohort-A analysis \[[@cit0012]\] severe PPM worsened the survival only in patients without post-procedural AR. Our study did not corroborate these findings, with no impact of PPM irrespective of AR presence; nonetheless, the low number of patients with severe mismatch precludes definite conclusions.

Limitations {#sec5.3}
-----------

The main limitation of our study is the small sample size and single-center character. On the other hand, our study presents for the first time prevalence, predictors and impact on mortality of patient-prosthesis mismatch in a Polish population. Furthermore, apart from the PARTNER trial analysis and study by Kukucka *et al.*, it is based on the largest subset of patients so far.

Conclusions {#sec6}
===========

Severe PPM after TAVI is rare, can be predicted by larger baseline BSA and does not seem to affect mid-term mortality or composite clinical outcome. Larger studies are needed to find different independent predictors of PPM and elucidate its impact in terms of device durability and long-term clinical efficacy.
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